Sangamo Therapeutics, Inc. SGMO Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sangamo Therapeutics, Inc. SGMO

SGMO 0.491

-7.3%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote (2)	4/6/2000 9:14:00 PM
From: Mike McFarland	of 368

ZFPs and Their Role in Angiogenesis It is widely accepted that disease processes could be controlled by the selective regulation of specific disease-related genes. The ZFP platform, with its ability to generate highly specific engineered transcription factors for the regulation of selected genes, is capable of rapidly and rationally producing proprietary pharmaceutical candidates for the therapeutic regulation of specific genes in a broad spectrum of clinical indications. Because they function at the DNA level, ZFPs can be precisely engineered to recognize a specific and unique DNA sequence within an entire genome. Such versatility in design and specificity in targeting means that ZFPs can be generated to discriminate between closely related genes. In addition, ZFPs can work through either activation or repression of disease-related genes. Sangamo has active research and development programs in the application of ZFPs to cardiovascular disease, cancer, and infectious diseases. noonanrusso.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next